← Eichor
Study identifier: NCT07617285 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML

Condition: AML · Refractory/Relapse Acute Myeloid Leukemia  ·  Sponsor: Peking University People's Hospital

PhasePhase 1
Planned participants27
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

A Clinical Study to Investigate the Safety and Efficacy of CT0890B in Patients with Relapsed/Refractory Acute Myeloid Leukemia.

This description comes directly from the study's public registry record.

Talk to the study team

Xiangyu Zhao, M.D,Ph.D  ·  010-88325531  ·  Zhao_xy@bjmu.edu.cn

Meng Lv, M.D., Ph.D  ·  010-88316617  ·  drlvmeng@bjmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Peking University People's HospitalBeijing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07617285